Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca confirms improved survival for HRPC patients

AstraZeneca confirms improved survival for HRPC patients

26th September 2007

AstraZeneca has presented phase II data which suggests that ZD4054 could offer improvement in survival for men with metastatic Hormone Resistant Prostate Cancer (HRPC) who are asymptomatic or mildly symptomatic for pain.

Data for ZD4054, a developing compound for the treatment of men with HRPC, showed a 45 per cent reduction in the risk of death when used in patients taking 10mg once-daily.

The results were delivered at the 14th European Congress of Clinical Oncology with Nick James, principal investigator of the study results, illustrating the limitations of the other hormonal therapies and the strain of chemotherapy on patients.

“The promising results from the EPOC study suggest that ZD4054 10mg once-daily has the potential to increase the median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC, with the benefit of a manageable side-effect profile and the convenience of once-daily oral dosing,” he added.

Alex Oldham, ZD4054 vice-president, insisted that AstraZeneca was committed to confirming the findings and further evaluating the compound by delivering a phase III clinical development programme.

Earlier this month, AstraZeneca announced the launch of a successful debut Eurobond transaction, with the company issuing 750 million euros (514 million pounds) of bonds in total.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.